Lawsuits filed by women who used the Depo-Provera birth control shot and were later diagnosed with meningioma brain tumors continue to grow in number across the United States. Federal cases have been consolidated into multidistrict litigation (MDL 3140) in the Northern District of Florida, and additional state-court filings, individual lawsuits, and a class action are moving forward in parallel.
As of early 2026, more than 3,100 cases have been filed nationwide, and that number is expected to keep climbing following the FDA's late-2025 update to the Depo-Provera prescribing information, which now includes information about the risk of meningioma.
The underlying medical research, including a 2024 study published in the BMJ, found that women exposed to medroxyprogesterone acetate face a substantially increased risk of intracranial meningioma compared to women who never used the shot.
What is less widely understood is that many of the women who would meet the eligibility criteria for these lawsuits do not realize they qualify. The following sections describe eight groups of potential claimants who are often overlooked or who assume the litigation does not apply to them.
Women Who Used Depo-SubQ Provera 104
Depo-SubQ Provera 104 is a lower-dose subcutaneous version of the Depo shot containing 104 mg of medroxyprogesterone acetate, compared to the 150 mg intramuscular formulation. Because it is administered differently and at a lower dose, many women who received the SubQ version assume that lawsuits over meningioma do not apply to them.
However, the active ingredient in Depo-SubQ Provera 104 is the same synthetic progestin that has been associated with meningioma in the underlying medical research, and the eligibility criteria used in the Depo-Provera meningioma litigation expressly include women who used the subcutaneous formulation.
SubQ users who received four or more injections and were later diagnosed with a cerebral meningioma may qualify to file a claim.
Generic Medroxyprogesterone Acetate Users
Many women who received their Depo injection from a pharmacy or clinic do not know whether they were given the brand-name Depo-Provera, the brand-name Depo-SubQ Provera 104, or an authorized generic version of medroxyprogesterone acetate.
According to the FDA's database of approved drugs, authorized generic versions of the injection have been available for years. Women who received the generic injection are generally treated the same as brand-name users for purposes of the Depo-Provera meningioma litigation, because the active ingredient and the underlying labeling responsibility flow from the same New Drug Application.
Patients who are not sure which version they received can typically determine the answer through pharmacy records, prescription histories, or by requesting copies of medical records from the clinic that administered the shots.
Women With Skull-Base Meningiomas
Meningiomas at the base of the skull, including those at the sphenoid wing, cavernous sinus, tuberculum sellae, and optic nerve sheath, are anatomically common in hormonally driven tumor growth. Published research on progestin exposure and meningioma incidence has identified the skull base as a frequent site of tumor development among women exposed to medroxyprogesterone acetate.
Symptoms of skull-base meningiomas often differ from those of tumors located higher on the brain surface. Patients may experience symptoms long before headaches or seizures appear, including:
- Progressive vision loss
- Double vision
- Facial numbness
- Hearing changes, or
- Loss of smell
These symptoms are frequently misattributed to migraines, sinus disease, or aging.
Women with a confirmed skull-base meningioma diagnosis after Depo-Provera use generally meet the cerebral meningioma eligibility criterion.
Women on Watchful Waiting or Observation
A significant number of meningiomas are managed through surveillance MRIs and clinical observation rather than immediate surgery or radiation. Women whose tumors are being monitored often assume they do not qualify to file a Depo-Provera lawsuit because they have not undergone a craniotomy or received Gamma Knife radiation.
The eligibility criteria for Depo-Provera meningioma claims require diagnosis of a cerebral meningioma, not surgical removal of the tumor.
Women on observation may also be eligible to pursue medical monitoring claims, which seek compensation for the ongoing imaging, neurology appointments, and neurocognitive evaluations that watchful waiting requires.
The cost of long-term surveillance can be substantial, and these expenses may be recoverable as damages even where the tumor has not yet required intervention.
Women With Incidentally Discovered Meningiomas
Meningiomas are commonly discovered by accident on imaging ordered for unrelated reasons. A CT scan after a car accident, an MRI for a sinus complaint, a neurological workup for an unrelated headache, or a stroke screening can all reveal an asymptomatic meningioma the patient had no idea was there.
According to medical guidance from the Mayo Clinic, incidental detection accounts for a meaningful share of all meningioma diagnoses. Because the tumor was found by accident, many women never connect their diagnosis to their prior Depo-Provera use.
The eligibility criteria for Depo-Provera meningioma lawsuits do not depend on how the tumor was discovered. Women diagnosed incidentally after meeting the use threshold may qualify on the same basis as women diagnosed after presenting with symptoms.
Long-Ago Depo-Provera Users
Depo-Provera has been on the U.S. market since 1992. Women who received the shot in the 1990s, 2000s, or early 2010s and stopped using it years ago often assume that the current lawsuits cannot apply to their case.
Meningiomas, however, can take years or even decades to grow large enough to produce symptoms or to be detected on imaging. The statute of limitations for Depo-Provera lawsuits varies by state, but typically depends on the discovery rule, which in many states starts the clock at the date of diagnosis or the date the patient reasonably should have connected the diagnosis to the medication, not at the date of the last injection.
The relationship between duration of Depo-Provera use and meningioma risk also strengthens claims for women with long historical exposure.
Wrongful Death and Family Member Claims
Some women diagnosed with meningioma after Depo-Provera use have died from post-surgical complications, untreated tumor progression, recurrence, or related neurological injury.
Information published by the American Association of Neurological Surgeons describes how location, size, and grade of a meningioma can lead to serious complications even where the tumor itself is non-cancerous.
Surviving spouses, adult children, parents, and other family members may have wrongful death and survival claims under state law that exist independently of any claim the deceased patient could have brought during her lifetime. Family members are often unaware that they have legal standing to file these claims on their own behalf.
Women With Recurrent or Multifocal Meningiomas
A meaningful portion of women diagnosed with a meningioma after Depo-Provera use are found to have either multiple tumors at the time of diagnosis (multifocal disease) or experience tumor recurrence after initial treatment.
Repeat craniotomies, second-line Gamma Knife or proton radiation following surgical recurrence, residual neurologic deficits, and ongoing seizure management substantially elevate the damages profile in these cases.
Women in this category often assume their case is too complicated, too unusual, or too far along to pursue, but in fact recurrent and multifocal cases generally meet the eligibility criteria for the Depo-Provera meningioma litigation under the strongest factual posture, and the heightened medical history can support more substantial claims for damages.
Contact a Depo-Provera Meningioma Attorney for a Free Case Evaluation
The eight groups described above represent women who often do not realize that they may qualify to file a Depo-Provera meningioma lawsuit.
Eligibility is broader than commonly understood, and the consolidation of federal cases in MDL 3140 along with active state-court and class action proceedings means that the litigation is moving forward across multiple tracks at once.
Women who used Depo-Provera or an authorized generic and were later diagnosed with a meningioma, regardless of formulation, tumor location, treatment pathway, or how long ago the injections occurred, may have legal options worth exploring.
Women who used the Depo shot and were diagnosed with a meningioma, as well as family members of women who passed away after a Depo-Provera meningioma diagnosis, can contact an experienced birth control litigation attorney to receive a free legal consultation and find out whether they qualify to take legal action.
